FDA Approves Adcetris / brentuximab vedotin + lenalidomide & rituximab in relapsed or refractory LBCL: Could This Change Standard Care? Lymphoma 2 Mins Read Date: February 12, 2025 FDA Approves Adcetris Overview The FDA has approved a new combination therapy for adults with relapsed…
Practical Tools & Expert Guidance for the Nurse Navigator and Clinical Team: Strategies to Reduce Treatment Disparities in Multiple Myeloma Multiple Myeloma 1 Min Read This immersive practice guide offers “how to†methods and day-to-day strategies via faculty commentary and a review of data and…
Multiple Myeloma Medication: MM6 Trial with Dexamethasone Multiple Myeloma 5 Mins Read The MM6 trial marks a significant advancement in multiple myeloma treatment, specifically for relapsed or refractory multiple myeloma (RRMM). For…
